Atara Biotherapeutics Inc (NASDAQ:ATRA) CEO Isaac E. Ciechanover sold 7,800 shares of Atara Biotherapeutics stock in a transaction on Thursday, December 13th. The stock was sold at an average price of $42.66, for a total transaction of $332,748.00. Following the transaction, the chief executive officer now owns 733,285 shares in the company, valued at approximately $31,281,938.10. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.
Shares of Atara Biotherapeutics stock opened at $41.72 on Friday. Atara Biotherapeutics Inc has a 1-year low of $14.50 and a 1-year high of $54.45.
Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings results on Tuesday, November 6th. The biotechnology company reported ($1.29) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.13) by ($0.16). Analysts expect that Atara Biotherapeutics Inc will post -4.82 earnings per share for the current year.
Several research analysts have recently weighed in on the stock. Zacks Investment Research upgraded shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Friday. Cowen reiterated a “buy” rating on shares of Atara Biotherapeutics in a research note on Friday, November 30th. Finally, BidaskClub upgraded shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, November 20th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $47.80.
COPYRIGHT VIOLATION NOTICE: This piece was first posted by BBNS and is the sole property of of BBNS. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://baseballnewssource.com/2018/12/16/atara-biotherapeutics-inc-atra-ceo-isaac-e-ciechanover-sells-7800-shares/3085102.html.
About Atara Biotherapeutics
Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company is developing tabelecleucel, an advanced T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.
Featured Story: How To Calculate Debt-to-Equity Ratio
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.